Durvalumab for the management of urothelial carcinoma: a short review on the emerging data and therapeutic potential

被引：14
|
作者：
Baldini, Capucine [1 ]
Champiat, Stephane [1 ]
Vuagnat, Perrine [1 ]
Massard, Christophe [1 ]
机构：
[1] Univ Paris Saclay, Drug Dev Dept, Gustave Roussy Canc Campus, Villejuif, France
来源：
ONCOTARGETS AND THERAPY | 2019年 / 12卷
关键词：
immunotherapy; PD-L1; inhibitor; durvalumab; urothelial carcinoma; bladder cancer; IMMUNE CHECKPOINT INHIBITOR; PHASE-I TRIALS; PROSPECTIVE VALIDATION; PROGNOSTIC SCORE; BLADDER-CANCER; CELL CARCINOMA; IMMUNOTHERAPY; CHEMOTHERAPY; MULTICENTER; CISPLATIN;
D O I：
10.2147/OTT.S141040
中图分类号：
Q81 [生物工程学（生物技术）]; Q93 [微生物学];
学科分类号：
071005 ; 0836 ; 090102 ; 100705 ;
摘要：
Urothelial carcinoma (UC) is the second most frequent urogenital malignancy with high incidence in the United States and Europe. Despite poor prognosis, new treatments have emerged with great efficacy and safety such as immune checkpoint inhibitors. Durvalumab, an anti Programmed Death Ligand 1, has been given breakthrough in UC in 2017 in patients who have disease progression during or following platinum-containing chemotherapy or who have disease progression,12 months after neoadjuvant or adjuvant treatment with platinum-containing chemotherapy. Food and Drug Administration approval was given on the results of the Phase I/II study of MEDI 4736. In this article, we will review available data on durvalumab in the treatment of locally advanced and metastatic UC and discuss therapeutic potential.
引用
收藏
页码：2505 / 2512
页数：8
相关论文
共 50 条
  • [41] Bladder Recurrence Following Upper Tract Surgery for Urothelial Carcinoma: A Contemporary Review of Risk Factors and Management Strategies
    Mertens, Laura S.
    Sharma, Vidit
    Matin, Surena F.
    Boorjian, Stephen A.
    Thompson, R. Houston
    Van Rhijn, Bas W. G.
    Masson-Lecomte, Alexandra
    EUROPEAN UROLOGY OPEN SCIENCE, 2023, 49 : 60 - 66
  • [42] Immunotherapy for renal cell carcinoma: New therapeutic combinations and adverse event management strategies: A review
    Ma, Xiaohan
    Chen, Jibing
    Chen, Sheng
    Lan, Xuan
    Wei, Zengzhao
    Gao, Hongjun
    Hou, Encun
    MEDICINE, 2024, 103 (30) : e38991
  • [43] Follow-up of the Urethra and Management of Urethral Recurrence After Radical Cystectomy: A Systematic Review and Proposal of Management Algorithm by the European Association of Urology-Young Academic Urologists: Urothelial Carcinoma Working Group
    Laukhtina, Ekaterina
    Moschini, Marco
    Soria, Francesco
    Andrea, David D.
    Teoh, Jeremy Yuen-Chun
    Mori, Keiichiro
    Albisinni, Simone
    Mari, Andrea
    Krajewski, Wojciech
    Cimadamore, Alessia
    Abufaraj, Mohammad
    Enikeev, Dmitry
    Neuzillet, Yann
    Giannarinim, Gianluca
    Xylinas, Evanguelos
    Kamat, Ashish M.
    Roupret, Morgan
    Babjuk, Marko
    Witjes, J. Alfred
    Shariat, Shahrokh F.
    Pradere, Benjamin
    EUROPEAN UROLOGY FOCUS, 2022, 8 (06): : 1635 - 1642
  • [44] Sphingosine-1-phosphate receptor 1 (S1PR1) expression in non-muscle invasive urothelial carcinoma: Association with poor clinical outcome and potential therapeutic target
    Go, Heounjeong
    Kim, Pil-Jong
    Jeon, Yoon Kyung
    Cho, Yong Mee
    Kim, Kyungeun
    Park, Bong-Hee
    Ku, Ja Yoon
    EUROPEAN JOURNAL OF CANCER, 2015, 51 (14) : 1937 - 1945
  • [45] Muscle-invasive bladder and urethral cancer recurrence after surgical management of upper tract urothelial carcinoma: A review of 305 patients
    Elawdy, Mohamed Mohamed
    Osman, Yasser
    Taha, Diaa Eldin
    El-halwagy, Samer
    TURKISH JOURNAL OF UROLOGY, 2018, 44 (03): : 213 - 220
  • [46] Clinical utility of pembrolizumab in the management of advanced solid tumors: an evidence-based review on the emerging new data
    du Rusquec, Pauline
    de Calbiac, Ombline
    Robert, Marie
    Campone, Mario
    Frenel, Jean Sebastien
    CANCER MANAGEMENT AND RESEARCH, 2019, 11 : 4297 - 4312
  • [47] Oral Mucositis Induced by Chemoradiotherapy in Head and Neck Cancer-A Short Review about the Therapeutic Management and the Benefits of Bee Honey
    Jicman , Daniela
    Sarbu, Mihaela Ionela
    Fotea, Silvia
    Nechifor, Alexandru
    Balan, Gabriela
    Anghele, Mihaela
    Vasile, Claudiu Ionut
    Niculet, Elena
    Sarbu, Nicolae
    Rebegea, Laura-Florentina
    Tatu, Alin Laurent
    MEDICINA-LITHUANIA, 2022, 58 (06):
  • [48] Comparative Effectiveness of Long-Acting GLP-1 Receptor Agonists in Type 2 Diabetes: A Short Review on the Emerging Data
    Chudleigh, Richard A.
    Platts, Julia
    Bain, Stephen C.
    DIABETES METABOLIC SYNDROME AND OBESITY-TARGETS AND THERAPY, 2020, 13 : 433 - 438
  • [49] Can magnetic resonance imaging differentiate muscle invasion (T2) and lamina propria invasion (T1) urothelial carcinoma of the bladder? A systematic review and meta-analysis of Vesical Imaging-Reporting and Data System accuracy
    Jazayeri, Seyed Behzad
    Dehghanbanadaki, Hojat
    Hosseini, Mahdie
    Taghipour, Pourya
    Bacchus, Michael W.
    Di Valerio, Elizabeth A.
    Sarabchian, Elnaz
    Balaji, K. C.
    Bandyk, Mark
    CURRENT UROLOGY, 2023, 17 (04) : 262 - 267
  • [50] Potential Benefit of Lymph Node Dissection During Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review by the European Association of Urology Guidelines Panel on Non-muscle-invasive Bladder Cancer
    Luis Dominguez-Escrig, Jose
    Peyronnet, Benoit
    Seisen, Thomas
    Bruins, Harman M.
    Yuan, Cathy Yuhong
    Babjuk, Marko
    Boehle, Andreas
    Burger, Maximilian
    Comperat, Eva M.
    Gontero, Paolo
    Lam, Thomas
    MacLennan, Steven
    Mostafid, Hugh
    Palou, Joan
    van Rhijn, Bas W. G.
    Sylvester, Richard J.
    Zigeuner, Richard
    Shariat, Shahrokh F.
    Roupret, Morgan
    EUROPEAN UROLOGY FOCUS, 2019, 5 (02): : 224 - 241
12345